Tahamtan Ahmadi
Genmab (United States)(US)Princeton Satellite Systems (United States)(US)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Monoclonal and Polyclonal Antibodies Research, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, Protein Degradation and Inhibitors
Most-Cited Works
- → Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma(2016)1,500 cited
- → Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma(2016)1,421 cited
- → Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma(2015)1,106 cited
- → Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma(2019)969 cited
- → Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study(2019)936 cited
- → Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma(2016)900 cited